Author:
Géresi Krisztina,Megyeri Attila,Szabó Boglárka,Szabó Zsolt,Aradi János,Németh József,Benkő Ilona
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference41 articles.
1. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10:345–353
2. Blouin RA, Warren GW (1999) Pharmacokinetic considerations in obesity. J Pharm Sci 88:1–7 Review
3. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. American Society of Clinical Oncology. J Clin Oncol 30:1553–1561 Review
4. De Jonge ME, Mathot RA, Van Dam SM, Beijnen JH, Rodenhuis S (2002) Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 50:251–255
5. Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD (2009) Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 64:115–122
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献